Nkarta (NKTX)
NASDAQ:NKTX
US Market

Nkarta (NKTX) Stock Price & Analysis

158 Followers

NKTX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.12 - $18.48
Previous Close$4.55
Volume148.57K
Average Volume (3M)401.44K
Market Cap
$222.65M
Enterprise Value-$9.39M
Total Cash (Recent Filing)$323.34M
Total Debt (Recent Filing)$91.29M
Price to Earnings (P/E)-1.8
Beta0.88
Aug 10, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.49
Shares Outstanding48,934,928
10 Day Avg. Volume275,692
30 Day Avg. Volume401,441
Standard Deviation0.28
R-Squared0.00098
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.64
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.07
Forecast
Price Target Upside442.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

NKTX FAQ

What was Nkarta’s price range in the past 12 months?
Nkarta lowest stock price was $3.12 and its highest was $18.48 in the past 12 months.
    What is Nkarta’s market cap?
    Currently, no data Available
    When is Nkarta’s upcoming earnings report date?
    Nkarta’s upcoming earnings report date is Aug 10, 2023 which is in 75 days.
      How were Nkarta’s earnings last quarter?
      Nkarta released its earnings results on May 11, 2023. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$0.674 by $0.044.
        Is Nkarta overvalued?
        According to Wall Street analysts Nkarta’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Nkarta pay dividends?
          Nkarta does not currently pay dividends.
          What is Nkarta’s EPS estimate?
          Nkarta’s EPS estimate is -$0.65.
            How many shares outstanding does Nkarta have?
            Nkarta has 48,934,930 shares outstanding.
              What happened to Nkarta’s price movement after its last earnings report?
              Nkarta reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.674. Following the earnings report the stock price went up 0.447%.
                Which hedge fund is a major shareholder of Nkarta?
                Among the largest hedge funds holding Nkarta’s share is RA Capital Management. It holds Nkarta’s shares valued at 28M.

                  ---

                  Nkarta Stock Smart Score

                  The Nkarta stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Nkarta

                  Nkarta Inc is a bio-pharmaceutical company focused on the discovery, development and commercialization of engineered, allogeneic, and off-the-shelf cell therapies to treat cancer.

                  ---

                  Top 5 ETFs holding NKTX

                  Name
                  Market Value
                  Smart Score
                  iShares NASDAQ US Biotechnology UCITS ETF
                  $104.07K
                  8
                  Invesco Nasdaq Biotechnology ETF
                  $4.14K
                  8
                  Up to five ETFs with an Outperform Smart Score that hold NKTX. The ETFs are listed according to market value of NKTX within the ETF

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Karyopharm Therapeutics
                  Monte Rosa Therapeutics
                  Biohaven Ltd.
                  Atara Biotherapeutics
                  Aura Biosciences Inc

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis